-
1
-
-
77449106972
-
At last, a RE-LYable alternative to warfarin for atrial fibrillation
-
Hankey GJ. At last, a RE-LYable alternative to warfarin for atrial fibrillation. Int J Stroke. 2009;4(6):454-5. doi: 10.1111/j.1747-4949.2009.00389.x.
-
(2009)
Int J Stroke
, vol.4
, Issue.6
, pp. 454-455
-
-
Hankey, G.J.1
-
2
-
-
79954456496
-
Dabigatran etexilate: a new oral thrombin inhibitor
-
Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011;123(13):1436-50. doi: 10.1161/CIRCULATIONAHA.110.004424.
-
(2011)
Circulation
, vol.123
, Issue.13
, pp. 1436-1450
-
-
Hankey, G.J.1
Eikelboom, J.W.2
-
3
-
-
84904675268
-
Dabigatran, bleeding, and the regulators
-
Moore TJ, Cohen MR, Mattison DR. Dabigatran, bleeding, and the regulators. BMJ. 2014;349:g4517. http://dx.doi.org/10.1136/bmj.g4517.
-
(2014)
BMJ.
, vol.349
, pp. g4517
-
-
Moore, T.J.1
Cohen, M.R.2
Mattison, D.R.3
-
4
-
-
84893160985
-
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)
-
Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63(4):321-8. doi: 10.1016/j.jacc.2013.07.104.
-
(2014)
J Am Coll Cardiol
, vol.63
, Issue.4
, pp. 321-328
-
-
Reilly, P.A.1
Lehr, T.2
Haertter, S.3
Connolly, S.J.4
Yusuf, S.5
Eikelboom, J.W.6
-
5
-
-
84881221868
-
Dabigatran: is there a role for coagulation assays in guiding therapy?
-
Brunetti L, Bandali F. Dabigatran: is there a role for coagulation assays in guiding therapy? Ann Pharmacother. 2013;47(6):828-40. doi: 10.1345/aph.1R720.
-
(2013)
Ann Pharmacother
, vol.47
, Issue.6
, pp. 828-840
-
-
Brunetti, L.1
Bandali, F.2
-
6
-
-
84857853180
-
Bleeding risk with dabigatran in the frail elderly
-
Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012;366(9):864-6. doi: 10.1056/NEJMc1112874.
-
(2012)
N Engl J Med
, vol.366
, Issue.9
, pp. 864-866
-
-
Harper, P.1
Young, L.2
Merriman, E.3
-
7
-
-
79960955075
-
The use of dabigatran in elderly patients
-
Legrand M, Mateo J, Aribaud A, Ginisty S, Eftekhari P, Huy PT, et al. The use of dabigatran in elderly patients. Arch Intern Med. 2011;171(14):1285-6. doi: 10.1001/archinternmed.2011.314.
-
(2011)
Arch Intern Med
, vol.171
, Issue.14
, pp. 1285-1286
-
-
Legrand, M.1
Mateo, J.2
Aribaud, A.3
Ginisty, S.4
Eftekhari, P.5
Huy, P.T.6
-
8
-
-
84945532654
-
The case for dosing dabigatran: how tailoring dose to patient renal function, weight, and age could improve the benefit-risk ratio
-
Safouris A, Triantafyllou N, Parissis J, Tsivgoulis. The case for dosing dabigatran: how tailoring dose to patient renal function, weight, and age could improve the benefit-risk ratio. Ther Adv Neurol Disord. 2015;8(6):245-54. doi: 10.1177/1756285615601360.
-
(2015)
Ther Adv Neurol Disord.
, vol.8
, Issue.6
, pp. 245-254
-
-
Safouris, A.1
Triantafyllou, N.2
Parissis, J.3
Tsivgoulis4
-
9
-
-
81855169531
-
Acutely injured patients on dabigatran
-
Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J Med. 2011;365(21):2039-40. doi: 10.1056/NEJMc1111095.
-
(2011)
N Engl J Med
, vol.365
, Issue.21
, pp. 2039-2040
-
-
Cotton, B.A.1
McCarthy, J.J.2
Holcomb, J.B.3
-
10
-
-
84883259388
-
Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation
-
Eikelboom JW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J, et al. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. J Am Coll Cardiol. 2013;62(10):900-8. doi: 10.1016/j.jacc.2013.05.042.
-
(2013)
J Am Coll Cardiol
, vol.62
, Issue.10
, pp. 900-908
-
-
Eikelboom, J.W.1
Connolly, S.J.2
Hart, R.G.3
Wallentin, L.4
Reilly, P.5
Oldgren, J.6
-
11
-
-
79958126202
-
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial
-
Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747.
-
(2011)
Circulation
, vol.123
, Issue.21
, pp. 2363-2372
-
-
Eikelboom, J.W.1
Wallentin, L.2
Connolly, S.J.3
Ezekowitz, M.4
Healey, J.S.5
Oldgren, J.6
-
12
-
-
84863660210
-
Dabigatran: uncharted waters and potential harms
-
Radecki RP. Dabigatran: uncharted waters and potential harms. Ann Intern Med. 2012;157(1):66-8. doi: 10.7326/0003-4819-157-1-201207030-00467.
-
(2012)
Ann Intern Med
, vol.157
, Issue.1
, pp. 66-68
-
-
Radecki, R.P.1
-
13
-
-
84857077970
-
Bleeding with dabigatran (Pradaxa)
-
Anonymous. Bleeding with dabigatran (Pradaxa). Med Lett Drugs Ther. 2011;53(1379-1380):98.
-
(2011)
Med Lett Drugs Ther.
, vol.53
, Issue.1379-1380
, pp. 98
-
-
-
14
-
-
84864350306
-
Hemopericardium in a patient treated with dabigatran etexilate
-
Barton CA, McMillian WD, Sadi Raza S, Keller RE. Hemopericardium in a patient treated with dabigatran etexilate. Pharmacotherapy. 2012;32(5):e103-7. doi: 10.1002/j.1875-9114.2012.01036.x.
-
(2012)
Pharmacotherapy
, vol.32
, Issue.5
, pp. e103-e107
-
-
Barton, C.A.1
McMillian, W.D.2
Sadi Raza, S.3
Keller, R.E.4
-
15
-
-
84862243930
-
Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients
-
Bene J, Said W, Rannou M, Deheul S, Coupe P, Gautier S. Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients. Ann Pharmacother. 2012;46(6), e14. doi: 10.1345/aph.1Q705.
-
(2012)
Ann Pharmacother
, vol.46
, Issue.6
-
-
Bene, J.1
Said, W.2
Rannou, M.3
Deheul, S.4
Coupe, P.5
Gautier, S.6
-
16
-
-
84859549864
-
Clinical challenges in a patient with dabigatran-induced fatal hemorrhage
-
Cano EL, Miyares MA. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother. 2012;10(2):160-3. doi: 10.1016/j.amjopharm.2012.02.004.
-
(2012)
Am J Geriatr Pharmacother
, vol.10
, Issue.2
, pp. 160-163
-
-
Cano, E.L.1
Miyares, M.A.2
-
17
-
-
84865045736
-
Fatal gastrointestinal hemorrhage after a single dose of dabigatran
-
Kernan L, Ito S, Shirazi F, Boesen K. Fatal gastrointestinal hemorrhage after a single dose of dabigatran. Clin Toxicol (Phila). 2012;50(7):571-3. doi: 10.3109/15563650.2012.705290.
-
(2012)
Clin Toxicol (Phila)
, vol.50
, Issue.7
, pp. 571-573
-
-
Kernan, L.1
Ito, S.2
Shirazi, F.3
Boesen, K.4
-
18
-
-
84865815830
-
Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation
-
Lillo-Le Louet A, Wolf M, Soufir L, Galbois A, Dumenil AS, Offenstadt G, et al. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation. Thromb Haemost. 2012;108(3):583-5. doi: 10.1160/TH12-03-0149.
-
(2012)
Thromb Haemost
, vol.108
, Issue.3
, pp. 583-585
-
-
Lillo-Le Louet, A.1
Wolf, M.2
Soufir, L.3
Galbois, A.4
Dumenil, A.S.5
Offenstadt, G.6
-
19
-
-
70349306707
-
Dabigatran versus warfarin in patients with atrial fibrillation
-
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. doi: 10.1056/NEJMoa0905561.
-
(2009)
N Engl J Med
, vol.361
, Issue.12
, pp. 1139-1151
-
-
Connolly, S.J.1
Ezekowitz, M.D.2
Yusuf, S.3
Eikelboom, J.4
Oldgren, J.5
Parekh, A.6
-
20
-
-
84859800192
-
Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment
-
Hariharan S, Madabushi R. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol. 2012;52(1 Suppl):119S-25S. doi: 10.1177/0091270011415527.
-
(2012)
J Clin Pharmacol
, vol.52
, Issue.1
, pp. 119S-125S
-
-
Hariharan, S.1
Madabushi, R.2
-
21
-
-
84866008554
-
Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation
-
Lehr T, Haertter S, Liesenfeld KH, Staab A, Clemens A, Reilly PA, et al. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol. 2011. doi: 10.1177/0091270011417716.
-
(2011)
J Clin Pharmacol
-
-
Lehr, T.1
Haertter, S.2
Liesenfeld, K.H.3
Staab, A.4
Clemens, A.5
Reilly, P.A.6
-
22
-
-
80055122488
-
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial
-
Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9(11):2168-75. doi: 10.1111/j.1538-7836.2011.04498.x.
-
(2011)
J Thromb Haemost
, vol.9
, Issue.11
, pp. 2168-2175
-
-
Liesenfeld, K.H.1
Lehr, T.2
Dansirikul, C.3
Reilly, P.A.4
Connolly, S.J.5
Ezekowitz, M.D.6
-
23
-
-
84864288063
-
The food and drug administration decision not to approve the 110 mg dose of dabigatran: give us a way out
-
Kowey PR, Naccarelli GV. The food and drug administration decision not to approve the 110 mg dose of dabigatran: give us a way out. Am J Med. 2012;125(8):732. doi: 10.1016/j.amjmed.2011.10.035.
-
(2012)
Am J Med
, vol.125
, Issue.8
, pp. 732
-
-
Kowey, P.R.1
Naccarelli, G.V.2
-
24
-
-
84965040095
-
-
Pradaxa® European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf.
-
-
-
-
25
-
-
77953168824
-
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity
-
van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116-27. doi: 10.1160/TH09-11-0758.
-
(2010)
Thromb Haemost
, vol.103
, Issue.6
, pp. 1116-1127
-
-
Ryn, J.1
Stangier, J.2
Haertter, S.3
Liesenfeld, K.H.4
Wienen, W.5
Feuring, M.6
-
26
-
-
79959782689
-
An assay to monitor bivalirudin levels on cardiopulmonary bypass
-
Salemi A, Agrawal YP, Fontes MA. An assay to monitor bivalirudin levels on cardiopulmonary bypass. Ann Thorac Surg. 2011;92(1):332-4. doi: 10.1016/j.athoracsur.2010.12.064.
-
(2011)
Ann Thorac Surg
, vol.92
, Issue.1
, pp. 332-334
-
-
Salemi, A.1
Agrawal, Y.P.2
Fontes, M.A.3
-
27
-
-
77952552934
-
Comparison of monitoring methods for lepirudin: impact of warfarin and lupus anticoagulant
-
Salmela B, Joutsi-Korhonen L, Saarela E, Lassila R. Comparison of monitoring methods for lepirudin: impact of warfarin and lupus anticoagulant. Thromb Res. 2010;125(6):538-44. doi: 10.1016/j.thromres.2010.02.002.
-
(2010)
Thromb Res
, vol.125
, Issue.6
, pp. 538-544
-
-
Salmela, B.1
Joutsi-Korhonen, L.2
Saarela, E.3
Lassila, R.4
-
28
-
-
84871744380
-
The effect of dabigatran on select specialty coagulation assays
-
Adcock DM, Gosselin R, Kitchen S, Dwyre DM. The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol. 2013;139(1):102-9. doi: 10.1309/AJCPY6G6ZITVKPVH139/1/102.
-
(2013)
Am J Clin Pathol
, vol.139
, Issue.1
, pp. 102-109
-
-
Adcock, D.M.1
Gosselin, R.2
Kitchen, S.3
Dwyre, D.M.4
-
29
-
-
84992512720
-
Pradaxa (dabigatran etexilate mesylate) prescribing information
-
(Accessed 2016 Apr 26).
-
Boehringer Ingelheim. Pradaxa (dabigatran etexilate mesylate) prescribing information. http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. (Accessed 2016 Apr 26).
-
-
-
-
30
-
-
80255134514
-
UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma
-
Delavenne X, Moracchini J, Laporte S, Mismetti P, Basset T. UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma. J Pharm Biomed Anal. 2012;58:152-6. doi: 10.1016/j.jpba.2011.09.018.
-
(2012)
J Pharm Biomed Anal
, vol.58
, pp. 152-156
-
-
Delavenne, X.1
Moracchini, J.2
Laporte, S.3
Mismetti, P.4
Basset, T.5
-
31
-
-
84880867914
-
Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore longitudinal study on aging: impact on renal drug dosing
-
Dowling TC, Wang ES, Ferrucci L, Sorkin JD. Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore longitudinal study on aging: impact on renal drug dosing. Pharmacotherapy. 2013. doi: 10.1002/phar.1282.
-
(2013)
Pharmacotherapy
-
-
Dowling, T.C.1
Wang, E.S.2
Ferrucci, L.3
Sorkin, J.D.4
-
32
-
-
47549086550
-
Serum cystatin C-based equation compared to serum creatinine-based equations for estimation of glomerular filtration rate in patients with chronic kidney disease
-
Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L. Serum cystatin C-based equation compared to serum creatinine-based equations for estimation of glomerular filtration rate in patients with chronic kidney disease. Clin Nephrol. 2008;70(1):10-7.
-
(2008)
Clin Nephrol
, vol.70
, Issue.1
, pp. 10-17
-
-
Hojs, R.1
Bevc, S.2
Ekart, R.3
Gorenjak, M.4
Puklavec, L.5
-
33
-
-
84904368894
-
A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time
-
Chin PK, Wright DF, Patterson DM, Doogue MP, Begg EJ. A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol. 2014. doi: 10.1111/bcp.12364.
-
(2014)
Br J Clin Pharmacol
-
-
Chin, P.K.1
Wright, D.F.2
Patterson, D.M.3
Doogue, M.P.4
Begg, E.J.5
-
34
-
-
79955480110
-
Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement
-
Freyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res. 2011;127(5):457-65. doi: 10.1016/j.thromres.2011.01.001.
-
(2011)
Thromb Res
, vol.127
, Issue.5
, pp. 457-465
-
-
Freyburger, G.1
Macouillard, G.2
Labrouche, S.3
Sztark, F.4
-
35
-
-
84923811544
-
Real-world variability in dabigatran levels in patients with atrial fibrillation
-
Chan NC, Coppens M, Hirsh J, Ginsberg JS, Weitz JI, Vanassche T, et al. Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost. 2015;13(3):353-9. doi: 10.1111/jth.12823.
-
(2015)
J Thromb Haemost
, vol.13
, Issue.3
, pp. 353-359
-
-
Chan, N.C.1
Coppens, M.2
Hirsh, J.3
Ginsberg, J.S.4
Weitz, J.I.5
Vanassche, T.6
-
36
-
-
84965011923
-
Dabigatran etexilate; deputy office director decisional memo application 22-512
-
October 19. Accessed 30 Oct 2013).
-
US Food and Drug Administration, Center for Drug Evaluation and Research. Dabigatran etexilate; deputy office director decisional memo application 22-512. October 19, 2010. http://www.Accessdata.Fda.Gov/drugsatfda_docs/nda/2010/022512orig1s000sumr.pdf Accessed 30 Oct 2013).
-
(2010)
-
-
-
37
-
-
84859591121
-
Dabigatran etexilate. Advisory committee briefing document
-
August 27. Accessed 30 Oct 2013.
-
US Food and Drug Administration, Center for Drug Evaluation and Research. Dabigatran etexilate. Advisory committee briefing document, August 27, 2010. http://www.Fda.Gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf Accessed 30 Oct 2013.
-
(2010)
-
-
-
38
-
-
84930181252
-
Real-world variability in dabigatran levels in patients with atrial fibrillation: comment
-
Douxfils J, Chatelain B, Dogne JM, Mullier F. Real-world variability in dabigatran levels in patients with atrial fibrillation: comment. J Thromb Haemost. 2015;13(6):1166-8. doi: 10.1111/jth.12880.
-
(2015)
J Thromb Haemost
, vol.13
, Issue.6
, pp. 1166-1168
-
-
Douxfils, J.1
Chatelain, B.2
Dogne, J.M.3
Mullier, F.4
-
39
-
-
37149005153
-
Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects
-
Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47(1):47-59.
-
(2008)
Clin Pharmacokinet
, vol.47
, Issue.1
, pp. 47-59
-
-
Stangier, J.1
Stahle, H.2
Rathgen, K.3
Fuhr, R.4
-
40
-
-
77949421739
-
Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study
-
Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49(4):259-68. doi: 10.2165/11318170-000000000-000004.
-
(2010)
Clin Pharmacokinet
, vol.49
, Issue.4
, pp. 259-268
-
-
Stangier, J.1
Rathgen, K.2
Stahle, H.3
Mazur, D.4
-
41
-
-
38749131205
-
The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans
-
Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386-99. doi: 10.1124/dmd.107.019083.
-
(2008)
Drug Metab Dispos
, vol.36
, Issue.2
, pp. 386-399
-
-
Blech, S.1
Ebner, T.2
Ludwig-Schwellinger, E.3
Stangier, J.4
Roth, W.5
-
42
-
-
84875938323
-
Genetic determinants of dabigatran plasma levels and their relation to bleeding
-
Pare G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127(13):1404-12. doi: 10.1161/CIRCULATIONAHA.112.001233.
-
(2013)
Circulation
, vol.127
, Issue.13
, pp. 1404-1412
-
-
Pare, G.1
Eriksson, N.2
Lehr, T.3
Connolly, S.4
Eikelboom, J.5
Ezekowitz, M.D.6
-
43
-
-
79958077792
-
Drug and dietary interactions of warfarin and novel oral anticoagulants: an update
-
Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011;31(3):326-43. doi: 10.1007/s11239-011-0561-1.
-
(2011)
J Thromb Thrombolysis
, vol.31
, Issue.3
, pp. 326-343
-
-
Nutescu, E.1
Chuatrisorn, I.2
Hellenbart, E.3
-
44
-
-
84860548394
-
Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy
-
Avecilla ST, Ferrell C, Chandler WL, Reyes M. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol. 2012;137(4):572-4. doi: 10.1309/AJCPAU7OQM0SRPZQ.
-
(2012)
Am J Clin Pathol
, vol.137
, Issue.4
, pp. 572-574
-
-
Avecilla, S.T.1
Ferrell, C.2
Chandler, W.L.3
Reyes, M.4
-
45
-
-
84859788384
-
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice
-
Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost. 2012;107(5):838-47. doi: 10.1160/TH11-10-0718.
-
(2012)
Thromb Haemost
, vol.107
, Issue.5
, pp. 838-847
-
-
Huisman, M.V.1
Lip, G.Y.2
Diener, H.C.3
Brueckmann, M.4
Ryn, J.5
Clemens, A.6
-
46
-
-
50449091991
-
Comparison of estimated glomerular filtration rate with estimated creatinine clearance in the dosing of drugs requiring adjustments in elderly patients with declining renal function
-
Spruill WJ, Wade WE, Cobb 3rd HH. Comparison of estimated glomerular filtration rate with estimated creatinine clearance in the dosing of drugs requiring adjustments in elderly patients with declining renal function. Am J Geriatr Pharmacother. 2008;6(3):153-60. doi: 10.1016/j.amjopharm.2008.07.002.
-
(2008)
Am J Geriatr Pharmacother
, vol.6
, Issue.3
, pp. 153-160
-
-
Spruill, W.J.1
Wade, W.E.2
Cobb, H.H.3
-
47
-
-
0016916438
-
Prediction of creatinine clearance from serum creatinine
-
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
-
(1976)
Nephron
, vol.16
, Issue.1
, pp. 31-41
-
-
Cockcroft, D.W.1
Gault, M.H.2
-
48
-
-
84880393661
-
Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital
-
Chin P, Vella-Brincat J, Walker S, Barclay M, Begg E. Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital. Intern Med J. 2013. doi: 10.1111/imj.12170.
-
(2013)
Intern Med J
-
-
Chin, P.1
Vella-Brincat, J.2
Walker, S.3
Barclay, M.4
Begg, E.5
-
49
-
-
84877692612
-
Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly
-
Hellden A, Odar-Cederlof I, Nilsson G, Sjoviker S, Soderstrom A, Euler M, et al. Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly. BMJ Open. 2013;3(4):e002686. doi: 10.1136/bmjopen-2013-002686.
-
(2013)
BMJ Open
, vol.3
, Issue.4
, pp. e002686
-
-
Hellden, A.1
Odar-Cederlof, I.2
Nilsson, G.3
Sjoviker, S.4
Soderstrom, A.5
Euler, M.6
-
50
-
-
84930187338
-
Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays
-
Douxfils J, Lessire S, Dincq AS, Hjemdahl P, Ronquist-Nii Y, Pohanka A, et al. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb Haemost. 2015;113(4):862-9. doi: 10.1160/TH14-09-0808.
-
(2015)
Thromb Haemost
, vol.113
, Issue.4
, pp. 862-869
-
-
Douxfils, J.1
Lessire, S.2
Dincq, A.S.3
Hjemdahl, P.4
Ronquist-Nii, Y.5
Pohanka, A.6
-
51
-
-
84877070596
-
In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban
-
He S, Wallen H, Bark N, Blomback M. In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban. J Thromb Thrombolysis. 2013;35(2):131-9. doi: 10.1007/s11239-012-0791-x.
-
(2013)
J Thromb Thrombolysis
, vol.35
, Issue.2
, pp. 131-139
-
-
He, S.1
Wallen, H.2
Bark, N.3
Blomback, M.4
-
52
-
-
84883227194
-
Dabigatran monitoring made simple?
-
Eikelboom JW, Weitz JI. Dabigatran monitoring made simple? Thromb Haemost. 2013;110(3):393-5. doi: 10.1160/TH13-07-0576.
-
(2013)
Thromb Haemost
, vol.110
, Issue.3
, pp. 393-395
-
-
Eikelboom, J.W.1
Weitz, J.I.2
-
53
-
-
84860528205
-
Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate
-
Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012;107(5):985-97. doi: 10.1160/TH11-11-0804.
-
(2012)
Thromb Haemost
, vol.107
, Issue.5
, pp. 985-997
-
-
Douxfils, J.1
Mullier, F.2
Robert, S.3
Chatelain, C.4
Chatelain, B.5
Dogne, J.M.6
-
54
-
-
79954534386
-
Laboratory assessment of new anticoagulants
-
Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med. 2011;49(5):761-72. doi: 10.1515/CCLM.2011.134.
-
(2011)
Clin Chem Lab Med
, vol.49
, Issue.5
, pp. 761-772
-
-
Samama, M.M.1
Guinet, C.2
-
55
-
-
84856593171
-
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
-
Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23(2):138-43. doi: 10.1097/MBC.0b013e32834f1b0c.
-
(2012)
Blood Coagul Fibrinolysis
, vol.23
, Issue.2
, pp. 138-143
-
-
Stangier, J.1
Feuring, M.2
-
56
-
-
84937203350
-
An idea for a mid to long term strategy for Pradaxa, showing EMA range comparisons
-
[Cited 15 March 2016].
-
Boehringer Ingelheim. An idea for a mid to long term strategy for Pradaxa, showing EMA range comparisons. 2014. Available from: http://journals.bmj.com/site/bmj/dabigatran/compared_ema.pdf [Cited 15 March 2016].
-
(2014)
-
-
-
57
-
-
84867357013
-
Perspective on dabigatran etexilate dosing - why not follow standard pharmacological principles?
-
Chin PK, Vella-Brincat JW, Barclay ML, Begg EJ. Perspective on dabigatran etexilate dosing - why not follow standard pharmacological principles? Br J Clin Pharmacol. 2012. doi: 10.1111/j.1365-2125.2012.04266.x.
-
(2012)
Br J Clin Pharmacol
-
-
Chin, P.K.1
Vella-Brincat, J.W.2
Barclay, M.L.3
Begg, E.J.4
-
58
-
-
84855876269
-
A new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk
-
Rosencher N, Albaladejo P. A new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk. Expert Opin Pharmacother. 2012;13(2):217-26. doi: 10.1517/14656566.2012.648614.
-
(2012)
Expert Opin Pharmacother
, vol.13
, Issue.2
, pp. 217-226
-
-
Rosencher, N.1
Albaladejo, P.2
-
59
-
-
84904634733
-
how the drug company withheld important analyses
-
Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ. 2014;349:g4670. doi: http://dx.doi.org/10.1136/bmj.g4670.
-
(2014)
BMJ.
, vol.349
, pp. g4670
-
-
Cohen, D.D.1
-
60
-
-
84937250263
-
Dose tailoring of dabigatran etexilate: obvious or excessive?
-
Douxfils J, Mullier F, Dogne JM. Dose tailoring of dabigatran etexilate: obvious or excessive? Expert Opin Drug Saf. 2015;14(8):1283-9. doi: 10.1517/14740338.2015.1049995.
-
(2015)
Expert Opin Drug Saf
, vol.14
, Issue.8
, pp. 1283-1289
-
-
Douxfils, J.1
Mullier, F.2
Dogne, J.M.3
-
61
-
-
77955994775
-
Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity
-
Ebner T, Wagner K, Wienen W. Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010;38(9):1567-75. doi: 10.1124/dmd.110.033696.
-
(2010)
Drug Metab Dispos
, vol.38
, Issue.9
, pp. 1567-1575
-
-
Ebner, T.1
Wagner, K.2
Wienen, W.3
-
62
-
-
0025885499
-
The effect of age on glucuronidation and sulphation of paracetamol by human liver fractions
-
Herd B, Wynne H, Wright P, James O, Woodhouse K. The effect of age on glucuronidation and sulphation of paracetamol by human liver fractions. Br J Clin Pharmacol. 1991;32(6):768-70.
-
(1991)
Br J Clin Pharmacol
, vol.32
, Issue.6
, pp. 768-770
-
-
Herd, B.1
Wynne, H.2
Wright, P.3
James, O.4
Woodhouse, K.5
-
63
-
-
74549132748
-
Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system
-
Court MH. Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev. 2010;42(1):209-24. doi: 10.3109/03602530903209288.
-
(2010)
Drug Metab Rev
, vol.42
, Issue.1
, pp. 209-224
-
-
Court, M.H.1
|